Biotech Targets Three Approval Filings by Year-End Amid Slowing COVID Vaccine Demand
- Moderna cuts R&D spending by 20% for 2025-2028 period
- Company aims for three vaccine approvals by end of the year
- Plans to trim pipeline, dropping five drug candidates
- Positive late-stage trial results for flu and RSV vaccines
- Expected sales range of $2.5 billion to $3.5 billion in 2025
- Aims to break even on operating cash cost basis by 2028
- No longer pursuing accelerated approval for experimental flu vaccine
- Phase 3 trial for norovirus vaccine planned
Moderna Inc. has announced plans to reduce its research and development spending by 20% for the period of 2025-2028, focusing on critical approvals over the next few years. The company aims to file for three vaccine regulatory approvals by the end of this year, including a next-generation COVID shot, a combination flu and COVID vaccine, and an expanded label for its RSV vaccine for high-risk adults under 60. Moderna has also dropped five drug candidates from its pipeline and expects sales to be in the range of $2.5 billion to $3.5 billion in 2025. The company is working on a phase 3 trial for its experimental norovirus vaccine, while casting doubt on accelerated approval for its experimental personalized cancer vaccine.
Factuality Level: 8
Factuality Justification: The article provides accurate and objective information about Moderna’s plans to cut research-and-development spending, reduce its pipeline, and focus on critical approvals. It also discusses the company’s recent clinical successes and challenges in the COVID vaccine market and RSV market. The article includes specific details about product launches, trial results, and future expectations.
Noise Level: 4
Noise Justification: The article provides relevant information about Moderna’s adjustments in its research and development spending, pipeline, and product launches due to the dwindling COVID vaccine market. It also mentions positive trial results for some of their vaccines and future plans. However, it could have provided more detailed analysis or insights into the company’s long-term strategies and potential consequences on the industry.
Public Companies: Moderna Inc. (MRNA), Pfizer Inc. (PFE), GSK PLC (GSK), Merck & Co. Inc. (MRK), S&P 500 (SPX)
Key People: Jamey Mock (Chief Financial Officer)
Financial Relevance: Yes
Financial Markets Impacted: Moderna’s stock performance and adjustments in its research-and-development spending impact financial markets, as well as the company’s sales projections for the next few years.
Financial Rating Justification: The article discusses Moderna’s changes to its research-and-development spending, product pipeline, and sales projections, which directly affect the company’s financial performance and market value. It also mentions the impact on the stock performance, making it financially relevant.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Extreme Rating Justification: There is no extreme event mentioned in the article.
Move Size: No market move size mentioned.
Sector: Healthcare
Direction: Down
Magnitude: Large
Affected Instruments: Stocks
www.marketwatch.com 
www.barrons.com www.barrons.com 
